Analysts have provided varied ratings for Alkermes (NASDAQ:ALKS) over the last quarter, with a total of 1 bullish, 1 somewhat bullish, and 3 indifferent ratings. The average 12-month price target for ALKS is now $32.6, down from the previous $33.67. Analysts from B of A Securities, JP Morgan, Piper Sandler, Mizuho, and UBS have made recent evaluations, with some raising and others lowering their price targets. Alkermes is a biotech company with a market cap below industry average, a revenue growth rate of 50.95% as of September 30, 2023, a net margin of 12.54%, an ROE of 3.62%, an ROA of 2.14%, and a debt-to-equity ratio of 0.28.